Aurora Cannabis (ACB) (ACBFF) has had a disappointing run so far this year, with the stock falling 32% YTD (year-to-date) to close at $8 Canadian on April 12, 2018. The current analyst ratings have changed to show that analysts are less bullish on the stock compared to the update in March. YTD, Horizons Marijuana Life Science ETF (HMMJ) has fallen 10.4%. Let’s look now at Aurora Cannabis’s ratings.
Aurora Cannabis: Rating changes
As of April 12, 2018, the consensus mean rating for Aurora Cannabis is 2.3 with an overall “buy” recommendation. The rating increased from 1.8 in March. An increase in rating indicates a bearishness for the stock.
In March, two analysts recommended a “strong buy” for the stock, and now there is only one with that rating. Two analysts now have “hold” recommendations compared to one in March. One analyst continues to have a “buy” recommendation in April.
The current consensus mean price target for Aurora Cannabis is $10.80 Canadian for the next 12-month period, which is higher than $8.75 Canadian in March. The median price target is also $10.80 Canadian, an increase from $9.20 Canadian in March.
Next, we’ll look at MedReleaf (MEDFF).